JP7587423B2 - アルツハイマー病のための遺伝子治療 - Google Patents

アルツハイマー病のための遺伝子治療 Download PDF

Info

Publication number
JP7587423B2
JP7587423B2 JP2020565341A JP2020565341A JP7587423B2 JP 7587423 B2 JP7587423 B2 JP 7587423B2 JP 2020565341 A JP2020565341 A JP 2020565341A JP 2020565341 A JP2020565341 A JP 2020565341A JP 7587423 B2 JP7587423 B2 JP 7587423B2
Authority
JP
Japan
Prior art keywords
promoter
disease
vector
aav2
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020565341A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019226832A5 (https=
JP2021525245A (ja
JP2021525245A5 (https=
Inventor
シェン，ジー
三世，レイモンド ジェー． ケレハー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of JP2021525245A publication Critical patent/JP2021525245A/ja
Publication of JPWO2019226832A5 publication Critical patent/JPWO2019226832A5/ja
Publication of JP2021525245A5 publication Critical patent/JP2021525245A5/ja
Application granted granted Critical
Publication of JP7587423B2 publication Critical patent/JP7587423B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23045—Memapsin 1 (3.4.23.45), i.e. beta-secretase 2 or BACE2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23046—Memapsin 2 (3.4.23.46), i.e. beta-secretase 1 or BACE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
JP2020565341A 2018-05-22 2019-05-22 アルツハイマー病のための遺伝子治療 Active JP7587423B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862675003P 2018-05-22 2018-05-22
US62/675,003 2018-05-22
PCT/US2019/033616 WO2019226832A1 (en) 2018-05-22 2019-05-22 Gene therapy for alzheimer's disease

Publications (4)

Publication Number Publication Date
JP2021525245A JP2021525245A (ja) 2021-09-24
JPWO2019226832A5 JPWO2019226832A5 (https=) 2022-05-26
JP2021525245A5 JP2021525245A5 (https=) 2022-05-26
JP7587423B2 true JP7587423B2 (ja) 2024-11-20

Family

ID=68617210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020565341A Active JP7587423B2 (ja) 2018-05-22 2019-05-22 アルツハイマー病のための遺伝子治療

Country Status (8)

Country Link
US (1) US12497608B2 (https=)
EP (1) EP3796980A4 (https=)
JP (1) JP7587423B2 (https=)
CN (1) CN112739419A (https=)
AU (1) AU2019272848A1 (https=)
CA (1) CA3100946A1 (https=)
IL (1) IL278813A (https=)
WO (1) WO2019226832A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3796980A4 (en) 2018-05-22 2022-03-23 The Brigham & Women's Hospital, Inc. NEW THERAPY FOR ALZHEIMER'S DISEASE
WO2020242892A1 (en) 2019-05-24 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
IL293285A (en) * 2019-11-29 2022-07-01 Paros Bio Inc Gene therapy for neurodegenerative disorders
WO2022261413A1 (en) * 2021-06-10 2022-12-15 The Brigham And Women’S Hospital, Inc. Cell-based assay for identification of activators of gamma-secretase
EP4399311A4 (en) * 2021-09-10 2025-11-26 Alnylam Pharmaceuticals Inc APP ARNI COMPOSITIONS AND THEIR METHODS OF USE FOR TREATMENT OR PREVENTION OF DISEASES CHARACTERIZED BY ENLARGED ENDOSOMES
CN116024270B (zh) * 2021-12-27 2025-07-22 中国科学院昆明动物研究所 一种app/psen1双转基因阿尔茨海默病树鼩模型的建立方法
CN115125244A (zh) * 2022-05-14 2022-09-30 吉林大学 构建阿尔兹海默症的兔模型方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013509890A (ja) 2009-11-09 2013-03-21 ジーンポッド セラピューティクス アーベー ｉｎｖｉｖｏでのニューロン特異的な最適化された連続ＤＯＰＡ合成用の新規ウイルスベクター構築物
JP2013107890A (ja) 1995-04-28 2013-06-06 Hsc Research & Development Ltd アルツハイマー病に関連する遺伝子配列およびタンパク質、ならびにその使用
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
EP1637608B1 (en) 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
PT733103E (pt) 1993-11-09 2004-07-30 Targeted Genetics Corp Criacao de elevados titulos de vectores de aav recombinantes
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
CA2187626C (en) 1994-04-13 2009-11-03 Michael G. Kaplitt Aav-mediated delivery of dna to cells of the nervous system
AU732508B2 (en) 1996-01-26 2001-04-26 Governing Council Of The University Of Toronto, The Nucleic acids and proteins related to Alzheimer's disease, and uses therefor
AR020107A1 (es) * 1998-07-09 2002-04-10 Boehringer Ingelheim Pharma Metodo para identificar una sustancia capaz de reducir o eliminar la actividad de la presenilinasa, las sustancias identificables con dicho metodo, el usode estas ultimas en la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y las composiciones farmaceuticas que
AU4992099A (en) * 1998-07-16 2000-02-07 Incyte Pharmaceuticals, Inc. Human presenilin-associated protein
US6979537B2 (en) 2000-01-10 2005-12-27 Scios, Inc. Methods for identifying inhibitors of neuronal degeneration
US6686449B2 (en) 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US7271313B2 (en) 2003-04-09 2007-09-18 The Brigham And Women's Hospital, Inc. Presenilin-deficient mouse model of age-dependent neurodegeneration and cognitive loss
CA2528963A1 (en) 2003-06-27 2005-01-13 Sirna Therapeutics, Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
WO2005037226A2 (en) 2003-10-17 2005-04-28 Georgia Tech Research Corporation Genetically engineered enteroendocrine cells for treating glucose-related metabolic disorders
PL1675956T3 (pl) 2003-10-21 2011-06-30 Merck Serono Sa Minimalna sekwencja DNA działająca jako insulator chromatyny i jej zastosowanie do wyrażania białek
US7498316B2 (en) 2004-04-06 2009-03-03 University Of Massachusetts Methods and compositions for treating gain-of-function disorders using RNA interference
CA2566519C (en) 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
JP2008500039A (ja) 2004-05-26 2008-01-10 ロゼッタ ジノミクス リミテッド ウイルスｍｉＲＮＡおよびウイルス関連ｍｉＲＮＡならびにその使用
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
WO2009042727A1 (en) 2007-09-24 2009-04-02 The Johns Hopkins University Immediate early gene arc interacts with endocytic machinery and regulates the trafficking and function of presenilin
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
CN103816540B (zh) * 2012-11-16 2018-01-02 中国科学院上海生命科学研究院 降低β‑抑制蛋白1与APH‑1蛋白的结合的物质在制备防治神经退行性疾病药物中的应用
HK1222673A1 (zh) * 2013-07-12 2017-07-07 The Children's Hospital Of Philadelphia Aav载体和用於抗aav(腺相关病毒)中和抗体的检测
GB201404470D0 (en) 2014-03-13 2014-04-30 Ucl Business Plc Therapeutic methods and materials
GB201413665D0 (en) * 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
US10350245B2 (en) 2015-01-21 2019-07-16 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
JP2018510160A (ja) * 2015-03-20 2018-04-12 ブルーバード バイオ， インコーポレイテッド ベクター製剤
WO2016209654A1 (en) * 2015-06-22 2016-12-29 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
EP4316588A3 (en) 2016-05-27 2024-05-15 Transcriptx, Inc. Treatment of primary ciliary dyskinesia with synthetic messenger rna
WO2018045022A1 (en) 2016-08-30 2018-03-08 University Of South Florida Adipose derived stem cell exosomes and uses thereof
CA3050264A1 (en) 2017-01-24 2018-08-02 Fred Hutchinson Cancer Research Center Systems and methods for hematopoietic cell expansion utilizing hydrogels
US11713470B2 (en) 2017-03-20 2023-08-01 University of Pittsburgh—of the Commonwealth System of Higher Education Targeted gene therapies for pain and other neuro-related disorders
ES3039647T3 (en) 2017-05-31 2025-10-23 Arcturus Therapeutics Inc Synthesis and structure of high potency rna therapeutics
JP7221275B2 (ja) 2017-08-03 2023-02-13 ボイジャー セラピューティクス インコーポレイテッド Ａａｖを送達するための組成物および方法
EP3796980A4 (en) 2018-05-22 2022-03-23 The Brigham & Women's Hospital, Inc. NEW THERAPY FOR ALZHEIMER'S DISEASE
WO2020242892A1 (en) 2019-05-24 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
IL293285A (en) 2019-11-29 2022-07-01 Paros Bio Inc Gene therapy for neurodegenerative disorders
US20230136245A1 (en) 2020-01-31 2023-05-04 Paros Bio, Inc. Gene therapy for neurodegenerative disorders using polynucleotide silencing and replacement

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013107890A (ja) 1995-04-28 2013-06-06 Hsc Research & Development Ltd アルツハイマー病に関連する遺伝子配列およびタンパク質、ならびにその使用
JP2013509890A (ja) 2009-11-09 2013-03-21 ジーンポッド セラピューティクス アーベー ｉｎｖｉｖｏでのニューロン特異的な最適化された連続ＤＯＰＡ合成用の新規ウイルスベクター構築物
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Alzheimer's & Dementia，2012，Vol.8, No.4S, Part 3，p.105
'Homo sapiens presenilin 1 (PSEN1), transcript variant 1, mRNA' DATABASE NCBI Nucleotide [online] accession:NM_000021 (Version:NM_000021.3), 07-AUG-2008, [retrieved on 2023.03.09], retrieved from the internet:，https://www.ncbi.nlm.nih.gov/nuccore/195947402?report=gb&sat=12&satkey=6105349
'Homo sapiens presenilin 1 (PSEN1), transcript variant 2, mRNA' DATABASE NCBI Nucleotide [online] accession:NM_007318 (Version:NM_007318.2), 07-AUG-2008, [retrieved on 2023.03.09], retrieved from the internet: ，https://www.ncbi.nlm.nih.gov/nuccore/195947396?sat=12&satkey=6105331
'Homo sapiens presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 1, mRNA' DATABASE NCBI Nucleotide [online] accession:NM_000447 (Version:NM_000447.2), 17-AUG-2007, [retrieved on 2023.03.09], retrieved from the internet: ，https://www.ncbi.nlm.nih.gov/nuccore/156105678?sat=11&satkey=9636665
'Homo sapiens presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2, mRNA' DATABASE NCBI Nucleotide [online] accession:NM_012486 (Version:NM_012486.2), 17-AUG-2007, [retrieved on 2023.03.09], retrieved from the internet: ，https://www.ncbi.nlm.nih.gov/nuccore/156105680?sat=11&satkey=9636666
J. Biol. Chem.，2006年，Vol.281, No.22，pp.15330-15336

Also Published As

Publication number Publication date
WO2019226832A1 (en) 2019-11-28
US12497608B2 (en) 2025-12-16
JP2021525245A (ja) 2021-09-24
IL278813A (en) 2021-01-31
AU2019272848A1 (en) 2020-12-03
CA3100946A1 (en) 2019-11-28
EP3796980A4 (en) 2022-03-23
US20210108186A1 (en) 2021-04-15
EP3796980A1 (en) 2021-03-31
CN112739419A (zh) 2021-04-30

Similar Documents

Publication Publication Date Title
JP7587423B2 (ja) アルツハイマー病のための遺伝子治療
JP7686573B6 (ja) アルツハイマー病のための遺伝子治療
JP7616995B2 (ja) 神経変性疾患のための遺伝子治療
WO2021108809A1 (en) Apoe gene therapy
US12583902B2 (en) DNA-binding domain transactivators and uses thereof
US20180161395A1 (en) Methods and pharmaceutical composition for the treatment of alzheimer's disease
AU2020393917A1 (en) Gene therapy for neurodegenerative disorders
US20230279405A1 (en) Dna-binding domain transactivators and uses thereof
CN116670291A (zh) 用于神经退行性疾病的基因疗法
US20250186621A1 (en) Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom
WO2024259064A1 (en) Materials and methods for the treatment of neurofibromin 1 mutations and diseases resulting therefrom
Hinsch et al. Interrogating the dependency of AAV capsids on AAVR for retinal transduction
CN119256091A (zh) 人室管膜特异性启动子及其用途
CA3140507A1 (en) Insulin gene therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220518

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241108

R150 Certificate of patent or registration of utility model

Ref document number: 7587423

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150